The Basics: Understanding Vulvar Intraepithelial Neoplasia (VIN)
At a Glance
Vulvar intraepithelial neoplasia (VIN) is a highly treatable precancerous condition where abnormal cells grow on the surface of the vulvar skin. It is primarily categorized into HPV-associated types (HSIL) and HPV-independent types (dVIN), both of which are treated to prevent cancer development.
If you have recently heard the term Vulvar Intraepithelial Neoplasia (VIN), it is completely normal to feel overwhelmed or anxious. The name sounds complex, and the word “neoplasia” often triggers fears of cancer. However, the most important thing to know right now is that VIN is a precancerous condition, not invasive cancer [1][2]. While it means there are abnormal cells on the surface of the vulvar skin that could potentially turn into cancer over time if left untreated, it is a highly manageable condition when caught early [3].
A diagnosis involving the genital area can also bring up intense feelings of vulnerability or embarrassment. Please know that you are not alone; VIN is a recognized medical condition that many women face, and your care team is there to help you navigate it with dignity and effective treatment [4][5].
Understanding the Name
The term Vulvar Intraepithelial Neoplasia (VIN) is a technical way of describing where the abnormal cells are located:
- Vulvar: Refers to the external female genitals.
- Intraepithelial: Means “within the skin layers.” The abnormal cells are confined to the surface layer of the skin and have not invaded deeper tissues [1].
- Neoplasia: Refers to a new, abnormal growth of cells.
Why the Terms May Seem Confusing
You may notice that different doctors or pathology reports use different sets of initials. This is because the official medical names for these lesions have been updated recently to better reflect how the condition develops. The World Health Organization (WHO) and the International Society for the Study of Vulvovaginal Disease (ISSVD) now categorize VIN into two main types based on their cause [1][6]:
-
HPV-Associated VIN (often called vHSIL or uVIN)
- This is the most common type and is caused by the Human Papillomavirus (HPV) [1].
- It is often referred to as HSIL (High-grade Squamous Intraepithelial Lesion) or uVIN (Usual-type VIN) [7].
- You might also hear the term LSIL (Low-grade Squamous Intraepithelial Lesion), which refers to mild changes that are generally not considered precancerous and often resolve on their own [7].
-
HPV-Independent VIN (often called dVIN)
- This type is not caused by HPV. Instead, it is usually linked to long-term skin irritation or conditions like lichen sclerosus (a condition that causes thin, white, itchy patches of skin) [2][8].
- This is called dVIN (Differentiated VIN). It is less common but requires close attention because it can progress to cancer more quickly than the HPV-associated type [9][10].
Stabilizing Facts
While a VIN diagnosis requires a plan for treatment or monitoring, there are several reasons to feel encouraged:
- It is not invasive cancer: By definition, VIN is limited to the top layer of the skin [1].
- Highly treatable: There are many ways to manage VIN, ranging from topical creams (like imiquimod) to laser therapy or small surgical procedures, depending on the type and extent of the cells [11][12].
- Preventative focus: The entire goal of treating VIN is to prevent cancer from ever developing. Regular follow-ups are the most effective tool for staying ahead of the condition [3][13].
- Preserving your health: Modern treatments focus not just on removing abnormal cells, but also on preserving the appearance and function of the vulvar area to maintain your quality of life [5][14].
Diagnosing the Specific Type
To tell these types apart, pathologists often use special “stains” on the tissue sample. You might see mentions of p16 (which usually points toward HPV-associated HSIL) or p53 (which is often used to help identify dVIN) in your medical records [15][16]. Knowing which type you have helps your doctor choose the most effective treatment for you.
Explore the Full Resource Guide
The Two Pathways: HPV-Associated vs. HPV-Independent VIN
Learn the critical differences between HPV-associated VIN (vHSIL) and HPV-independent dVIN. Understand your pathology report, p16 vs p53 markers, and treatments.
Symptoms, Diagnosis, and Your Pathology Report
Learn the symptoms of Vulvar Intraepithelial Neoplasia (VIN) and how it is diagnosed. Understand your pathology report, including vHSIL, dVIN, p16, and p53.
Treatment Options and Recovery
Learn about treatment options for Vulvar Intraepithelial Neoplasia (VIN). Understand when surgery, lasers, or creams are used, and what to expect in recovery.
Life After Treatment: Surveillance and Prevention
Learn what to expect after Vulvar Intraepithelial Neoplasia (VIN) treatment. Understand recurrence risks, follow-up schedules, self-exams, and prevention.
Common questions in this guide
Is Vulvar Intraepithelial Neoplasia (VIN) considered cancer?
What is the difference between uVIN (HSIL) and dVIN?
What do p16 and p53 mean on my vulvar pathology report?
How is Vulvar Intraepithelial Neoplasia treated?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my pathology report indicate if my VIN is 'HPV-associated' (HSIL/uVIN) or 'differentiated' (dVIN)?
- 2.Was p16 or p53 staining used to confirm this diagnosis?
- 3.What is the estimated risk of this specific area progressing to invasive cancer if left untreated?
- 4.Do you see any signs of underlying skin conditions, like lichen sclerosus, that might be contributing to this?
- 5.Given my diagnosis, do you recommend surgery, topical creams, or laser treatment for my specific case?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (16)
- 1
Precancerous Squamous Lesions of the Vulva.
Welch KC, Haefner HK, Saunders NA
Obstetrics and gynecology 2025; doi:10.1097/AOG.0000000000006150.
PMID: 41380160 - 2
[Vulvar intraepithelial neoplasias].
Plantier F
Annales de pathologie 2022; (42(1)):58-67 doi:10.1016/j.annpat.2021.02.014.
PMID: 33744030 - 3
Vulval Intraepithelial Neoplasia 3: A Clinico-Pathological Review in a Tertiary Care Centre Over 10 Years.
Bassetty KC, Thomas A, Chandy RG, et al.
Journal of obstetrics and gynaecology of India 2022; (72(Suppl 1)):334-339 doi:10.1007/s13224-022-01659-2.
PMID: 35928075 - 4
Psychological distress among cancer patients in African countries: a systematic review and meta-analysis study.
Kibralew G, Wassie YA, Kelebie M, et al.
BMC psychology 2025; (13(1)):128 doi:10.1186/s40359-025-02447-z.
PMID: 39962603 - 5
Combination of surgery and laser for the treatment of extensive VIN3 and vulval condyloma: A case report.
Farzaneh F, Khalili L, Rakhshani N, et al.
Annals of medicine and surgery (2012) 2022; (78()):103763 doi:10.1016/j.amsu.2022.103763.
PMID: 35734690 - 6
[Update on precursors of vulvar carcinoma].
Guillon S, Cavadias I, Brun P, et al.
Gynecologie, obstetrique, fertilite & senologie 2021; (49(6)):538-546 doi:10.1016/j.gofs.2020.11.002.
PMID: 33166702 - 7
Pathologic features of anogenital precancerous high-grade squamous intraepithelial lesion (squamous cell carcinoma in situ).
Xue R, Elbendary A, Valdebran M, et al.
Journal of cutaneous pathology 2016; (43(9)):735-9 doi:10.1111/cup.12732.
PMID: 27152742 - 8
The Prevalence of Lichen Sclerosus in Patients With Vulvar Squamous Cell Carcinoma.
Davick JJ, Samuelson M, Krone JT, Stockdale CK
International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists 2017; (36(4)):305-309 doi:10.1097/PGP.0000000000000341.
PMID: 27801760 - 9
The Vulvar Cancer Risk in Differentiated Vulvar Intraepithelial Neoplasia: A Systematic Review.
Voss FO, Thuijs NB, Vermeulen RFM, et al.
Cancers 2021; (13(24)) doi:10.3390/cancers13246170.
PMID: 34944788 - 10
Incidence and Risk Factors for Recurrence and Progression of HPV-Independent Vulvar Intraepithelial Neoplasia.
Voss FO, van Beurden M, Veelders KJ, et al.
Journal of lower genital tract disease 2024; (28(2)):153-159 doi:10.1097/LGT.0000000000000794.
PMID: 38518213 - 11
Aesthetic Outcome and Psychosexual Distress After Treatment for Vulvar High-Grade Squamous Intraepithelial Lesions.
Trutnovsky G, Holter M, Gold D, et al.
Journal of lower genital tract disease 2024; (28(1)):48-53 doi:10.1097/LGT.0000000000000785.
PMID: 37934148 - 12
Management of Vulvar Cancer Precursors: A Survey of the International Society for the Study of Vulvovaginal Disease.
Green N, Adedipe T, Dmytryshyn J, et al.
Journal of lower genital tract disease 2020; (24(4)):387-391 doi:10.1097/LGT.0000000000000559.
PMID: 32986387 - 13
Vulval Intraepithelial Neoplasia: A 15-Year Review of Treatment Outcomes in a UK Centre.
McGowan MA, Haldar K, Pathiraja P, et al.
Cureus 2025; (17(10)):e95074 doi:10.7759/cureus.95074.
PMID: 41280995 - 14
The Role of Photodynamic Therapy in the Treatment of Vulvar Intraepithelial Neoplasia.
Tosti G, Iacobone AD, Preti EP, et al.
Biomedicines 2018; (6(1)) doi:10.3390/biomedicines6010013.
PMID: 29393881 - 15
Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva.
Liu YA, Ji JX, Almadani N, et al.
Histopathology 2021; (78(3)):424-433 doi:10.1111/his.14238.
PMID: 32799363 - 16
Expression of CK17 and SOX2 in Vulvar Intraepithelial Neoplasia: A Comprehensive Analysis of 150 Vulvar Lesions.
Thuijs NB, Voss FO, Ewing-Graham PC, et al.
Cancers 2024; (16(23)) doi:10.3390/cancers16233966.
PMID: 39682153
This page provides educational information about Vulvar Intraepithelial Neoplasia (VIN). It is not a substitute for professional medical advice, diagnosis, or treatment from your gynecologist or healthcare provider.
Get notified when new evidence is published on Vulvar intraepithelial neoplasia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.